• ELCC 2023
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Girard Keyslides
    • Rudin Keyslides
    • Waterhouse Keyslides
    • Majem Tarruella Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Linardou Keyslide
    • Garrido Lopez Keyslides
    • Li Keyslides
    • Makharadze Keyslides
  • Highlights Newsletter 3
    • Podcast with dr. Jordi Remón-Masip about the safety and efficacy of osimertinib versus sequential gefitinib and osimertinib in patients with EGFR-mutant NSCLC
    • Podcast with Prof. Niels Reinmuth about the patterns of response in metastatic NSCLC after 2 and 4 cycles of chemotherapy, alone or with durvalumab ± tremelimumab
    • Podcast with Prof. Saadettin Kiliçkap about cemiplimab monotherapy as first-line treatment of patients with brain metastases from advanced NSCLC
• ASCO GU 2023
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 1
    • Agarwal Keyslides
    • Burotto Keyslides
    • Necchi Keyslides
    • Hussain Keyslides
    • Atkins Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 2
    • Bamias Keyslides
    • Huddart Keyslides
    • Clarke Keyslides
    • Westhofen Keyslides
  • Highlights Newsletter 3
    • Podcast with Prof. Daniel Petrylak about pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer
    • Podcast with Dr. Matthew D. Galsky about the efficacy and safety of atezolizumab plus platinum/gemcitabine for the first-line treatment of locally advanced or metastatic urothelial carcinoma
    • Podcast with Dr. Alan H. Bryce about the survival outcomes of rucaparib vs. docetaxel or second-generation androgen pathway inhibitor therapy in mCRPC patients
    • Podcast with Dr. Vadim Koshkin and Tanya Jindal about biomarkers of response to enfortumab vedotin in advanced urothelial carcinoma
• SABCS 2022
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • O’Regan Keyslides
    • Lu Keyslides
    • Krop Keyslides
    • Kaklamani Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Johnston Keyslides
    • Turner Keyslides
    • Bidard Keyslides
    • Kang Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Bardia Keyslides
    • Partridge Keyslides
    • Montagna Keyslides
    • De Censi Keyslides
  • Highlights Newsletter 4
    • Podcast with Prof. Sara Hurvitz about treatment with trastuzumab deruxtecan vs. trastuzumab emtansine in HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03
    • Podcast with Dr. Judy Boughey about the impact of breast conservation therapy on local recurrence in patients with multiple ipsilateral breast cancer: Results from the Alliance trial
    • Podcast with Prof. Mafalda Oliveira about different doses of camizestrant monotherapy vs. fulvestrant in advanced ER+/ HER2- breast cancer: Results from SERENA-2
    • Podcast with Prof. Erica Mayer about fulvestrant, palbociclib, and avelumab treatment combinations for endocrine pre-treated ER+/HER2- metastatic breast cancer: Results from the PACE trial
• EBCC 2022
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Hagenaars Keyslides
    • Kunkler Keyslides
    • Jhaveri Keyslides
    • Miglietta Keyslides
• ESMO 2022
  • Highlights Newsletter 1
    • Podcast with Dr. Laurence Buisseret about first-line chemoimmunotherapy with durvalumab, paclitaxel, and carboplatin with or without the anti-CD73 antibody oleclumab to treat advanced or metastatic triple-negative breast cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Haanen Keyslides
    • Ray-Coquard Keyslides
    • Swanton Keyslides
    • Kasper Keyslides
  • Highlights Newsletter 2
    • Podcast with Prof. Richard S. Finn about lenvatinib plus pembrolizumab vs. lenvatinib as first-line therapy for advanced hepatocellular carcinoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Parker Keyslides
    • Schrag Keyslides
    • Motzer Keyslides
    • Dzienis Keyslides
  • Highlights Newsletter 3
    • Podcast with Prof. Jean-Pascal Machiels about the primary results of the phase 3 KEYNOTE-412 study: pembrolizumab with chemoradiation vs. placebo plus chemoradiation for locally advanced head and neck squamous cell carcinoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Goetz Keyslides
    • Kudo Keyslides
    • Lee Keyslides
    • Orlandi Keyslides
  • Highlights Newsletter 4
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 4
    • Choueiri Keyslides
    • Johnson Keyslides
    • Eggermont Keyslides
    • Kurtz Keyslides
    • Capdevila Castillon Keyslides
  • Highlights Newsletter 5
    • Podcast with Prof. Anne Demols and Prof. Francesco Sclafani about the highlights from ESMO 2022 on gastrointestinal cancer
    • Podcast with Prof. Christof Vulsteke about the highlights from ESMO 2022 on gynaecological cancer
    • Podcast with Dr. Willem Lybaert about the highlights from ESMO 2022 on head and neck cancer
    • Podcast with Prof. Lore Decoster about the highlights from ESMO 2022 on lung cancer
• WCLC 2022
  • Highlights Newsletter 1
    • Podcast with Prof. Melina Marmarelis about the safety and efficacy of amivantamab and lazertinib in combination with platinum-based chemotherapy in relapsed/refractory EGFR-mutated NSCLC
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Wu Keyslides
    • Li Keyslides
    • Provencio Keyslides
    • Rudin Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 2
    • Felip Keyslides
    • Fan Keyslides
    • Altorki Keyslides
    • Reck Keyslides
    • Goldman Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 3
    • Levy Keyslides
    • Peeters Keyslides
    • Thomas Keyslides
    • Rodriguez-Abreu Keyslides
    • Murray Keyslides
  • Highlights Newsletter 4
    • Podcast with Prof. Johan Vansteenkiste about the challenges and opportunities with immunotherapy in the treatment of patients with squamous cell carcinoma of the lung
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Felip Keyslides
    • Provencio Keyslides
    • Li Keyslides
    • Levy Keyslides
• WCGIC 2022
  • Highlights Newsletter 1
    • Podcast with Prof. Erika Martinelli about evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients with metastatic colorectal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides Newsletter 1
    • Janjigian Keyslides
    • Chau Keyslides
    • Heinemann keyslides
  • Highlights Newsletter 2
    • Podcast with Prof. Arndt Vogel about the outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the Phase 3 HIMALAYA study
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides Newsletter 2
    • Wang Keyslides
    • Melero keyslides
    • Salem Keyslides
  • Highlights Newsletter 3
    • Podcast with Dr. Daniele Rossini about modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients (TRIPLETE study)
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides Newsletter 3
    • Wyrwicz Keyslides
    • Vogel Keyslides
    • Yoon Keyslides
  • Highlights Newsletter 4
    • Podcast with Prof. Erika Martinelli about evidence of therapeutic effectiveness of third-line cetuximab rechallenge in appropriately selected patients with metastatic colorectal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides Newsletter 4
    • Chau Keyslides
    • Janjigian Keyslides
    • Wang Keyslides
• EADO 2022
  • Dr. Wissam discusses the highlights on adjuvant therapy in cutaneous melanoma
  • Prof. Nikkels on the TELESPOT project: a Belgian teledermoscopy system in primary healthcare centres for early detection of skin cancer
  • Prof. Hoeller about the potential role for adjuvant therapy in the treatment of intermediate risk melanoma patients
• ASCO 2022
  • Highlights Newsletter 1
    • Podcast with Prof. Cornelis J.A. Punt about FOLFOXIRI + bevacizumab vs. FOLFOX/FOLFIRI + bevacizumab in patients with initially unresectable CRLM and right-sided and/or RAS/BRAFV600E-mutated primary tumour
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Spira Keyslides
    • Motzer Keyslides
    • Hofman Keyslides
    • Rugo Keyslides
  • Highlights Newsletter 2
    • Podcast with Prof. Christian Blank about personalised response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in resectable stage III melanoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Yoshino Keyslides
    • Qin Keyslides
    • Rudin Keyslides
    • Monk Keyslides
  • Highlights Newsletter 3
    • Podcast with Dr. Antonio Avallone and Dr. Alfredo Budillon about randomised intermittent or continuous panitumumab plus FOLFIRI for first-line treatment of patients with RAS/BRAF wild-type metastatic colorectal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • McCabe Keyslides
    • Modi Keyslides
    • Long Keyslides
    • Noronha Keyslides
  • Highlights Newsletter 4
    • Dr. Kevin Punie talks us through some of the key data in the field of breast cancer
    • Prof. Dr. Hans Prenen shares his highlights in the field of gastro-intestinal cancer
    • Dr.Willem Lybaert discusses some of the key data in the field of head and neck cancer
    • Prof. Dr. Lore Decoster will walk us through the highlights in thoracic oncology
    • Dr. Daan De Maeseneer will share his highlights in the field of urogenital cancer
• ELCC 2022
  • Highlights Newsletter 1
    • Podcast with Dr. Delvys Rodriguez-Abreu about pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: 3-year follow-up of Keynote-598
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Reinmuth Keyslides
    • Lu Keyslides
    • Yang Keyslides
    • Lyu Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 2
    • Zhou Keyslides
    • Shi Keyslides
    • Felip Keyslides
    • Li Keyslides
    • Wolf Keyslides
  • Highlights Newsletter 3
    • Podcast with Dr. Delvys Rodriguez-Abreu about pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC with PD-L1 tumor proportion score ≥ 50%: 3-year follow-up of Keynote-598
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Reinmuth Keyslides
    • Lyu Keyslides
    • Shi Keyslides
    • Yang Keyslides
• ASCO GU 2022
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 1
    • Saad Keyslides
    • Grivas Keyslides
    • Petrylak Keyslides
    • Smith Keyslides
    • Powles Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 2
    • de Vries Keyslides
    • Choueiri Keyslides
    • Loriot Keyslides
    • Hofman Keyslides
    • Grimm Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides Newsletter 3
    • Saad Keyslides
    • Powles Keyslides
    • Smith Keyslides
    • de Vries Keyslides
    • Loriot Keyslides
• ASCO GI 2022
  • Highlights Newsletter 1
    • Podcast with dr. Wainberg about the updated results from the phase III Keynote-062 trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Kuang Keyslides
    • Ikeda Keyslides
    • Yamaguchi Keyslides
    • Metges Keyslides
  • Highlights Newsletter 2
    • Podcast with dr. Antonio D'Alessio about real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Shitara Keyslides
    • Hamaguchi Keyslides
    • Oh Keyslides
    • Bekaii-Saab Keyslides
  • Highlights Newsletter 3
    • Podcast with prof. Romain Cohen about one year of nivolumab plus ipilimumab for MSI/dMMR metastatic colorectal cancer patients
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Yoshino Keyslides
    • Kato Keyslides
    • Abou-Alfa Keyslides
    • André Keyslides
  • Highlights Newsletter 4
    • Podcast with dr. Antonio D'Alessio about real-world use of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Kato Keyslides
    • Oh Keyslides
    • Kuang Keyslides
    • Yoshino Keyslides
• SABCS 2021
  • Highlights Newsletter 1
    • PODCAST with Prof. Michael Gnant about adjuvant palbociclib in HR+/HER2- early breast cancer - the final results from the PALLAS trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Goodwin Keyslides
    • André Keyslides
    • Xu Keyslides
    • Bardia Keyslides
  • Highlights Newsletter 2
    • Podcast with Prof. Dr. Sara Hurvitz about subgroup analyses from the randomised phase III DESTINY-Breast03 study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Schmid Keyslides
    • Bidard Keyslides
    • Xu Keyslides
    • Carey Keyslides
  • Highlights Newsletter 3
    • Podcast with Dr. Patricia Ganz about the quality of life results from the OlympiA trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Bradley Keyslides
    • Cortés Keyslides
    • Krop Keyslides
    • Jhaveri Keyslides
  • Highlights Newsletter 4
    • PODCAST with Prof. Michael Gnant about adjuvant palbociclib in HR+/HER2- early breast cancer - the final results from the PALLAS trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Goodwin Keyslides
    • André Keyslides
    • Xu Keyslides
    • Carey Keyslides
• ESMO 2021
  • Highlights Newsletter 1
    • Professor Gerhardt Attard - Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa)
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Nishio Keyslides
    • Cortés Keyslides
    • Colombo Keyslides
    • Weiss Keyslides
  • Highlights Newsletter 2
    • PODCAST of dr. Robin Cornelissen about efficacy and safety of poziotinib in treatment-naïve NSCLC harboring HER2 exon 20 mutations
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Schmid Keyslides
    • Janjigian Keyslides
    • Miura Keyslides
    • Fizazi Keyslides
  • Highlights Newsletter 3
    • PODCAST of prof. dr. Helena Earl about Meta-Analysis of Reduced Duration adjuvant Trastuzumab in the treatment of HER2 positive Early Breast Cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Seligmann Keyslides
    • Luke Keyslides
    • Baudin Keyslides
    • Oosting Keyslides
  • Highlights Newsletter 4
    • PODCAST with prof. Eric Pujade-Lauraine about maintenance olaparib rechallenge in patients with ovarian carcinoma previously treated with a PARP inhibitor
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Manich Keyslides
    • Felip Keyslides
    • Grohé Keyslides
    • Brown Keyslides
  • Highlights Newsletter 5
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 5
    • Oosting Keyslides
    • Cortés Keyslides
    • Schmid Keyslides
    • Janjigian Keyslides
• WCLC 2021
  • Highlights Newsletter 1
    • PODCAST with Drs. Daphne Dumoulin, MD about Lurbinectedin in Pre-Treated Patients With Small Cell Lung Cancer and Malignant Pleural Mesothelioma in a Real World Setting
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Smeltzer Keyslides
    • Bondarenko Keyslides
    • Chauhan Keyslides
    • Pastorino Keyslides
  • Highlights Newsletter 2
    • PODCAST with Dr. Johnson about Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Gadgeel Keyslides
    • Huang Keyslides
    • Spira Keyslides
    • Carbone Keyslides
  • Highlights Newsletter 3
    • PODCAST with Dr. Alexander Spira about Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Evangelist Keyslides
    • Ramalingam Keyslides
    • Altorki Keyslides
    • Camidge Keyslides
  • Highlights Newsletter 4
    • PODCAST with Dr. Johnson about Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Evangelist Keyslides
    • Bondarenko Keyslides
    • Gadgeel Keyslides
    • Pastorino Keyslides
• WCGIC 2021
  • Highlights Newsletter 1
    • Podcast with dr. Zev Wainberg about the preliminary data from a phase 1b trial evaluating the safety and efficacy of tiragolumab combined with atezolizumab for patients with metastatic oesophageal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Tempero Keyslides
    • Gkika Keyslides
    • Taieb Keyslides
    • André Keyslides
  • Highlights Newsletter 2
    • In this podcast, Dr. Lisa Salvatore discusses the primary analysis results of the phase II AVANA study, which evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced rectal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Janjigian Keyslides
    • Strosberg Keyslides
    • Shah Keyslides
    • Abou-Alfa Keyslides
  • Highlights Newsletter 3
    • In this podcast, Dr. Zev Wainberg discusses preliminary data from a phase 1b trial evaluating the safety and efficacy of tiragolumab combined with atezolizumab for patients with metastatic oesophageal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Maio Keyslides
    • Ducreux Keyslides
    • Ajani Keyslides
    • Sunakawa Keyslides
  • Highlights Newsletter 4
    • PODCAST with dr. Lisa Salvatore about the primary analysis results of the phase II AVANA study, which evaluated preoperative chemoradiotherapy, combined with avelumab, in patients with locally advanced rectal cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Tempero Keyslides
    • Shah Keyslides
    • Ducreux Keyslides
    • Janjigian Keyslides
• ASCO 2021
  • Highlights Newsletter 1
    • PODCAST with prof. Thomas Powles about Keynote-426: Pembrolizumab plus axitinib as a first-line treatment option for patients with advanced clear cell renal cell carcinoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Bauml Keyslides
    • Chau Keyslides
    • Yuan Keyslides
    • Xu Keyslides
  • Highlights Newsletter 2
    • PODCAST with dr. Josephine Lopes Cardozo: outcomes of patients with an ultralow risk 70-gene signature in the MINDACT trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Dummer Keyslides
    • Wakelee Keyslides
    • Mileshkin Keyslides
    • Morris Keyslides
  • Highlights Newsletter 3
    • PODCAST with Prof. Karim Fizazi: first results of the PEACE-1 trial in men with de novo metastatic castration-sensitive prostate cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Perreault Keyslides
    • Tutt Keyslides
    • Modest Keyslides
    • Choueiri Keyslides
  • Highlights Nieuwsbrief 4
    • PODCAST with dr. Thierry André about the final overall survival results of the Keynote-177 trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Brose Keyslides
    • Roth Keyslides
    • Yoshino Keyslides
    • Lipson Keyslides
  • Highlights Newsletter 5
    • PODCAST with dr. Leisha Emens about the influence of the tumour microenvironment on the clinical outcomes of triple-negative breast cancer patients who are treated with atezolizumab plus nab-paclitaxel
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 5
    • Roth Keyslides
    • Yoshino Keyslides
    • Bauml Keyslides
    • Tutt Keyslides
• ASCO GI 2021
  • Highlights Newsletter 1
    • podcast with dr. Kai Keen Shiu about the phase III KEYNOTE-177 study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Yoshida Keyslides
    • Koyanagi Keyslides
    • Tabernero Keyslides
    • Javle Keyslides
  • Highlights Newsletter 2
    • Podcast with dr. Zev Wainberg about the phase II FIGHT study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Henriksen Keyslides
    • Boige Keyslides
    • Zhu Keyslides
    • Katz Keyslides
  • Highlights Newsletter 3
    • Podcast with prof. dr. Eric Van Cutsem about the phase II study evaluating first-line treatments of unresectable mCRC
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Lee Keyslides
    • Van Cutsem Keyslides
    • Finn Keyslides
    • Garcia-Carbonero Keyslides
  • Highlights Newsletter 4
    • Podcast with prof.dr. Jean Luc van Laethem about the KEYNOTE 224 trial: phase II study evaluating pembrolizumab monotherapy
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Lee Keyslides
    • Koyanagi Keyslides
    • Tabernero Keyslides
    • Javle Keyslides
• ASCO GU 2021
  • Highlights Newsletter 1
    • PODCAST with prof. Michael Hofman about the phase II TheraP trial: Lutetium 177 for metastatic castration-resistant prostate cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Joffe keyslides
    • Balar Keyslides
    • Motzer Keyslides
    • Appleman Keyslides
  • Highlights Newsletter 2
    • Podcast with prof. Thomas Powles about the EV 301 trial: Phase III study of enfortumab vedotin versus chemotherapy in pre-treated metastatic urothelial carcinoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Rathkopf keyslides
    • Pal keyslides
    • De Bono Keyslides
    • Siva Keyslides
  • Highlights Newsletter 3
    • Podcast with prof. Grant Stewart about the NAXIVA trial: a phase II study of neoadjuvant axitinib to reduce venous tumour thrombus in clear cell renal cell carcinoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Ghadjar Keyslides
    • Choueiri Keyslides
    • Fizazi Keyslides
    • Rose Keyslides
  • Highlights Newsletter 4
    • Podcast with prof. Thomas Powles about the EV 301 trial: Phase III study of enfortumab vedotin versus chemotherapy in pre-treated locally advanced or metastatic urothelial carcinoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Appleman Keyslides
    • Rose Keyslides
    • Rathkopf keyslides
    • Siva Keyslides
• WCLC 2020
  • Highlights Newsletter 1
    • Podcast with prof. Michael Boyer about the phase III Keynote 598 study of ipilimumab and pembrolizumab vs. pembrolizumab monotherapy, in metastatic non-small cell lung cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Kilickap Keyslides
    • Belderbos Keyslides
    • Cornelissen Keyslides
    • Spira Keyslides
  • Highlights Newsletter 2
    • Podcast with prof. dr. Bob Li about the CodeBreak 100 trial: phase II study of KRAS¬- G12C inhibition with Sotorasib in non-small cell lung cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Wu Keyslides
    • Zhou Keyslides
    • Zhao Keyslides
    • Lee Keyslides
  • Highlights Newsletter 3
    • Podcast with dr. Joshua Sabari about the CHRYSALIS study: Phase I trial of amivantamab in non-small cell lung cancer with EGFR exon 20 insertion mutations
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Nakagawa Keyslides
    • Fennell Keyslides
    • Novello Keyslides
    • Reck Keyslides
  • Highlights Newsletter 4
    • Podcast with prof. Dean Fennell and prof. Gareth Griffiths about the phase III CONFIRM trial: Nivolumab monotherapy in relapsed mesothelioma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Belderbos Keyslides
    • Wu Keyslides
    • Reck Keyslides
    • Lee Keyslides
• ESMO 2020
  • Highlights Newsletter 1
    • PODCAST with dr. Mayer about the PALLAS study regarding adjuvant palbociclib for HR+/HER2- early breast cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Tsuboi Keyslides
    • Choueiri Keyslides
    • De Bono Keyslides
    • Miles Keyslides
  • Highlights Newsletter 2
    • PODCAST with dr. Eggermont about pembrolizumab after complete resection of high-risk stage III melanoma
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Nakagawa Keyslides
    • Moehler Keyslides
    • Johnston Keyslides
    • Solomon Keyslides
  • Highlights Newsletter 3
    • PODCAST with dr. Banerjee about the impact of COVID-19 on oncology professionals
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Le Pechoux Keyslides
    • Kato Keyslides
    • Tran Keyslides
    • Colombo Keyslides
  • Highlights Newsletter 4
    • PODCAST with dr. Bardia about the ASCENT study examining sacituzumab govitecan in metastatic triple-negative breast cancer
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Tsuboi Keyslides
    • Choueiri Keyslides
    • Moehler Keyslides
    • Le Pechoux Keyslides
• WCGIC 2020
  • Highlights Newsletter 1
    • PODCAST with prof. Bruno Sangro about the CheckMate 459 trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Ramaswamy Keyslides
    • Wainberg Keyslides
    • Yamaguchi Keyslides
    • Grothey Keyslides
  • Highlights Newsletter 2
    • Podcast with dr. Manish R. Patel about the efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Li Keyslides
    • Rovers Keyslides
    • Sunakawa Keyslides
    • Yoon Keyslides
  • Highlights Newsletter 3
    • Podcast with dr. Manish R. Patel about the efficacy and safety of entrectinib in NTRK fusion-positive gastrointestinal cancers
    • Presentation 2
    • Presentation 1
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Li Keyslides
    • Yamaguchi Keyslides
    • Ramaswamy Keyslides
    • Rovers Keyslides
• ASCO 2020
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • PODCAST Javier Cortes about the KEYNOTE-355 trial
  • Keyslides Newsletter 1
    • Warner Keyslides
    • André Keyslides
    • Fares Keyslides
    • Poveda Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • PODCAST Nadia Harbeck about the KAITLIN study
  • Keyslides Newsletter 2
    • Powles Keyslides
    • Motzer Keyslides
    • Lorenzen Keyslides
    • Gogas Keyslides
  • Highlights Newsletter 3
    • PODCAST: Egbert Smit about the DESTINY-Lung01 trial
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Conroy Keyslides
    • Mirza Keyslides
    • Cardoso Keyslides
    • Li Keyslides
  • Highlights Newsletter 4
    • PODCAST Maha Hussain about the IMvigor010 study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Herbst Keyslides
    • Lin Keyslides
    • Hauschild Keyslides
    • Fizazi Keyslides
  • Highlights Newsletter 5
    • PODCAST Luis Paz-Ares about the CASPIAN study
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 5
    • Cardoso Keyslides
    • Warner Keyslides
    • Mirza Keyslides
    • André Keyslides
• ESMO 2019
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Patrick Neven
  • Keyslides Newsletter 1
    • Ray-Coquard Keyslides
    • Smith Keyslides
    • Yau Keyslides
    • Larkin Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with prof. Laura Q.M. Chow
  • Keyslides Newsletter 2
    • Sledge Keyslides
    • González-Martín Keyslides
    • Ramalingam Keyslides
    • Hussain Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Noel Clarke
  • Keyslides Newsletter 3
    • Tabernero Keyslides
    • Peters Keyslides
    • Schmid Keyslides
    • De Wit Keyslides
  • Highlights Newsletter 4
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Jean-Pascal Machiels
  • Keyslides Newsletter 4
    • Sledge Keyslides
    • Peters Keyslides
    • Hussain Keyslides
    • Ray-Coquard Keyslides
• ASCO 2019
  • Highlights Newsletter 1
    • Video interview with Josep Tabernero
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 1
    • Garon Keyslides
    • Guigay Keyslides
    • Sastre Keyslides
    • Chi Keyslides
  • Highlights Newsletter 2
    • Video interview with Daniel P. Petrylak
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 2
    • Tap Keyslides
    • Hurvitz Keyslides
    • Cascone Keyslides
    • Liszkay Keyslides
  • Highlights Newsletter 3
    • Video interview with Sara Hurvitz
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 3
    • Sweeney Keyslides
    • Penson Keyslides
    • Nakagawa Keyslides
    • Tempero Keyslides
  • Highlights Newsletter 4
    • Video interview with Hedy Kindler
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides Newsletter 4
    • Guigay Keyslides
    • Sweeney Keyslides
    • Nakagawa Keyslides
    • Tap Keyslides
• ASCO 2018
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Robert M. Jotte
  • Keyslides Newsletter 1
    • Earl Keyslides
    • Stadler Keyslides
    • Tsimberidou Keyslides
    • Baselga Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Arnoud Méjean
  • Keyslides Newsletter 2
    • Slamon Keyslides
    • Bisogno Keyslides
    • Lopes Keyslides
    • Conroy Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Geertjan van Tienhoven
  • Keyslides Newsletter 3
    • Borgheai Keyslides
    • Sparano Keyslides
    • Quenet Keyslides
    • Weber Keyslides
  • Highlights Newsletter 4
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Patrick Neven
  • Keyslides Newsletter 4
    • Sparano Keyslides
    • Conroy Keyslides
    • Stadler Keyslides
    • Bisogno Keyslides
• ESMO 2018
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Peter Schmid
  • Keyslides Newsletter 1
    • Smith Keyslides
    • André Keyslides
    • Papadimitrakopoulou Keyslides
    • Rini Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Jonathan Ledermann
  • Keyslides Newsletter 2
    • Cristofanilli Keyslides
    • Parker Keyslides
    • Sakai Keyslides
    • Mehanna Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. John Haanen
  • Keyslides Newsletter 3
    • Wu Keyslides
    • Lenz Keyslides
    • Burtness Keyslides
    • Arkenau Keyslides
  • Highlights Newsletter 4
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Jonathan Ledermann
  • Keyslides Newsletter 4
    • Lenz Keyslides
    • Cristofanilli Keyslides
    • Parker Keyslides
    • Mehanna Keyslides
• ESMO 2017
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Corey Langer
  • Keyslides Newsletter 1
    • Sydes Keyslides
    • Saura Keyslides
    • Wainberg Keyslides
    • Paz-Ares Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Bernard Escudier
  • Keyslides Newsletter 2
    • Westeel Keyslides
    • Voest Keyslides
    • Di Leo Keyslides
    • Weber Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Prof. Daniel Petrylak
  • Keyslides Newsletter 3
    • De Wit keyslides
    • Ramalingam Keyslides
    • Gupta Keyslides
    • Hauschild Keyslides
• ASCO 2017
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video-interview with Prof. Dr. Nicholas James
  • Keyslides Newsletter 1
    • Primrose Keyslides
    • Hoskins Keyslides
    • Wu Keyslides
    • Tredan Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video-interview with Prof. Dr. Günter von Minckwitz
  • Keyslides Newsletter 2
    • Grothey Keyslides
    • Fizazi Keyslides
    • Mok Keyslides
    • Lambertini Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video-interview with Prof. Ronald de wit
  • Keyslides Newsletter 3
    • Shaw Keyslides
    • Robson Keyslides
    • Scherpereel Keyslides
    • Basch Keyslides
    • Smith Keyslides
• ESMO 2016
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with prof. dr. E. Van Cutsem
  • Keyslides Newsletter 1
    • Mirza Keyslides
    • Ellis Keyslides
    • Barlesi Keyslides
    • Robert Keyslides
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Interview with professor B. Neyns
  • Keyslides Newsletter 2
    • Fizazi keyslides
    • Choueiri Keyslides
    • Langer Keyslides
    • Gronchi Keyslides
  • Highlights Newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Interview with professor H. Wildiers
  • Keyslides Newsletter 3
    • Reck Keyslides
    • Ravaud Keyslides
    • Scagliotti Keyslides
    • Harrington Keyslides
• SABCS 2016
  • Highlights newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Interview with Prof. Dr. Hans Wildiers
  • Keyslides Newsletter 1
    • Rimawi Keyslides
    • Robertson Keyslides
    • Bourdeanu Keyslides
    • Kornblum Keyslides
    • Han Keyslides
  • Highlights newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video interview with Prof. Wiebren Tjalma
  • Keyslides Newsletter 2
    • Bachelot Keyslides
    • DiLeo Keyslides
    • Classe Keyslides
    • Steger Keyslides
    • Brufsky Keyslides
  • Highlights newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video interview with Prof. Dr. Veronique Cocquyt
  • Keyslides newsletter 3
    • Swain Keyslides
    • Karakatsanis Keyslides
    • Yardley Keyslides
    • Dalmasso Keyslides
    • De Azambuja Keyslides
  • Highlights Newsletter 4
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Interview with Prof. Ruth O'Ryan
  • Keyslides Newsletter 4
    • Cocquyt Keyslides
    • Classe Keyslides
    • Han Keyslides
    • Dalmasso Keyslides
    • Robertson Keyslides
• ECC 2015
  • Highlights Newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with professor J. O'Sullivan
  • Keyslides Newsletter 1
    • Sharma Keyslides
    • Lambertini Keyslides
    • Pietanza Keyslides
    • Robert Keyslides
    • Video interview with professor J. O'Sullivan
  • Highlights Newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Video interview with Professor E. van Cutsem
  • Keyslides Newsletter 2
    • Choueiri Keyslides
    • Larkin Keyslides
    • Horn Keyslides
    • Ruszniewski Keyslides
    • Video interview with Professor E. van Cutsem
• ESMO 2014
  • Highlights newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video-interview with Prof. Hans Wildiers
  • Keyslides newsletter 1
    • Temel keyslides
    • Ahn keyslides
    • Machiels keyslides
    • Symonds Keyslides
    • Amant keyslides
  • Highlights newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video-interview with Didier Verhoeven
  • Keyslides newsletter 2
    • Kim keyslides
    • Ryan Keyslides
    • Goss Keyslides
    • Fasching Keyslides
    • Weber Keyslides
  • Highlights newsletter 3
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video interview with Paul Germonpré
  • Keyslides newsletter 3
    • Gligorov Keyslides
    • Lenz Keyslides
    • Mok Keyslides
    • McArthur Keyslides
    • Zhu Keyslides
  • Highlights newsletter 4
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video interview with Prof. Ahmad Awada
  • Keyslides newsletter 4
    • Vansteenkiste Keyslides
    • Robert Keyslides
    • Chasen Keyslides
    • Von Minckwitz Keyslides
    • Stahel Keyslides
  • Highlights newsletter 5
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Video interview with Prof. Philippe Collard
  • Keyslides newsletter 5
    • Gligorov Keyslides
    • Lenz Keyslides
    • Goss Keyslides
    • Fasching Keyslides
    • Symonds Keyslides
• ESMO 2012
  • Highlights newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides newsletter 1
    • Zielinski Keyslides
    • Pivot Keyslides
    • Verma Keyslides
    • Qi Keyslides
  • Highlights newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
  • Keyslides newsletter 2
    • Pivot Keyslides
    • Gelber Keyslides
    • Arnedos Keyslides
    • Beauchemin Keyslides
• SABCS 2012
  • Highlights newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides newsletter 1
    • Martin Keyslides
    • Sgroi Keyslides
    • Yarnold Keyslides
  • Highlights newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides newsletter 2
    • Cameron Keyslides
    • Kaufman Keyslides
    • Finn Keyslides
• EBCC 2012
  • Highlights newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides newsletter 1
    • Donker Keyslides
    • Gnant Keyslides
    • Linn Keyslides
  • Highlights newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
  • Keyslides newsletter 2
    • Krekel Keyslides
    • Ligibel Keyslides
    • Vulsteke Keyslides
• SABCS 2011
  • Highlights newsletter 1
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
  • Keyslides newsletter 1
    • Gnant Keyslides
    • Galimberti Keyslides
    • Paterson Keyslides
    • Hortobagyi Keyslides
    • Liu Keyslides
  • Highlights newsletter 2
    • Presentation 1
    • Presentation 2
    • Presentation 3
    • Presentation 4
    • Presentation 5
    • Presentation 6
  • Keyslides newsletter 2
    • Gianni Keyslides
    • Van den Broek Keyslides
    • Baselga Keyslides
    • De Boer Keyslides
    • Solin Keyslides